This company has shut down. Theonys is no longer operating — its last tracked round was a Venture - Series Unknown in 2022.
Explore the Startup GraveyardTheonys is harnessing the power of tRNA to pioneer an entirely new class of genomic medicines.
Theonys has raised $2.9M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in August 2022.
Theonys is headquartered in Cambridge, United States.
Theonys is harnessing the power of tRNA to pioneer an entirely new class of genomic medicines.
Theonys is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Theonys — Funding & Investors." VCBacked, August 25, 2022, https://www.vcbacked.co/company/theonys. Accessed August 14, 2026.
VCBacked. (2022). Theonys — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/theonys
{{cite web |title=Theonys — Funding & Investors |url=https://www.vcbacked.co/company/theonys |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated